Detalhe da pesquisa
1.
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Mol Cancer
; 22(1): 120, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516818
2.
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC Cancer
; 23(1): 1080, 2023 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946136
3.
Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.
Int J Mol Sci
; 24(8)2023 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37108755
4.
FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890888
5.
Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life.
Front Oncol
; 12: 863057, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35330711
6.
Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?
Lung Cancer
; 161: 98-107, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34560426